Lornoxicam is a non-steroidal anti-inflammatory drug with analgesic property which is used for the better treatment of pain and arthritics. Moreover the site of absorption of lornoxicam is in the intestine and the short half life of 3 to 4 hr. Due to the short half life the frequency of administration is more and it produced peptic ulceration, gastrointestinal disturbance and gastric bleeding. Therefore the present investigation was concerned with the development of the sustained release matrix tablets, which after oral administration were designed to prolong the duration of action. Lornoxicam Sustained release matrix tablet was prepared by wet granulation method using Acrypol 912G and Eudragit RSPO in formulation. 32 full factorial design applied for the optimization of satisfactory batch. Acrypol 912G(X1) and Eudragit RSPO(X2) selected as independent parameter % cumulative drug release at 2, 6 and 10 hr were selected as dependent parameter. The dissolution profile of all the batches was fitted to zero-order, first-order, Higuchi, Hixson Crowell and K-Peppas models to ascertain the kinetic modeling of drug release. From the result showed that Q2, Q6 and Q10 strongly depend on the independent parameter. In vitro drug release of factorial batches compared with theoretical release profile and indicate that batch F7 was most satisfactory batch. It was observed that the combination ratio of Acrypol 912G and Eudragit RSPO have distinct effect on in vitro drug release profile. Release rate of lornoxicam was decrease with increased the total polymer concentration. Mechanism of drug release was explained by K-Peppas equation and found that diffusion-erosion occurs by anomalous transport (non-Fickian) release is predominant.
Loading....